Abstract
New approaches to drug discovery are unlocking enormous therapeutic potential residing in cancer-specific molecules. Brachyury is emerging as an exciting new drug target for the rare bone cancer chordoma. Here, recent advances targeting Brachyury in chordoma are discussed and how these might open doors to the targeting of other, more common cancer types.
Keywords:
brachyury; chordoma; small molecule inhibitors.
Copyright © 2020 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents / pharmacology*
-
Antineoplastic Agents / therapeutic use
-
Biomarkers, Tumor / analysis
-
Biomarkers, Tumor / antagonists & inhibitors*
-
Biomarkers, Tumor / metabolism
-
Bone Neoplasms / diagnosis
-
Bone Neoplasms / drug therapy*
-
Bone Neoplasms / pathology
-
Chordoma / diagnosis
-
Chordoma / drug therapy*
-
Chordoma / pathology
-
Computer Simulation
-
Crystallography, X-Ray
-
Drug Discovery
-
Fetal Proteins / analysis
-
Fetal Proteins / antagonists & inhibitors*
-
Fetal Proteins / metabolism
-
Fetal Proteins / ultrastructure
-
Humans
-
Models, Molecular
-
Protein Domains
-
T-Box Domain Proteins / analysis
-
T-Box Domain Proteins / antagonists & inhibitors*
-
T-Box Domain Proteins / metabolism
-
T-Box Domain Proteins / ultrastructure
Substances
-
Antineoplastic Agents
-
Biomarkers, Tumor
-
Fetal Proteins
-
T-Box Domain Proteins
-
Brachyury protein